| Patient | Jack London |
|---|---|
| Date of birth | 1987-01-12 |
| Identifiers | MRN HR-ET010-SYN; SSN (made up) 000-10-4482 |
| Document date | 2026-09-15 |
| Author | Eleanor Whitcombe-Ibe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review. [S]
Mr. London has not had a drink since the evening two weeks ago when he sprained his ankle and drank two large whiskies for the pain; he talked that evening through with his counselor and has set a plan for pain and late afternoons. He takes naltrexone every morning without nausea. The ankle is much better with the brace and he has stopped the gel. He writes every morning and swims at the hour he used to take his first drink. He takes losartan 50 mg without dizziness; his home readings average 136/86. He is sleeping six hours. He has had no opioid or anti-inflammatory medicine. His hepatitis B, hepatitis C and HIV tests were negative. [S]
| Element | Detail |
|---|---|
| Alcohol | One evening two weeks ago; none since |
| PEth | 36 ng/mL, from 410 |
| Kidneys | Creatinine 1.96 mg/dL, eGFR 44; potassium 4.8; urine albumin 128 mg/g |
| Liver tests | AST 34, ALT 29, GGT 82 U/L |
| Vitamin D | 24 ng/mL |
| Mood | PHQ-9 5, item 9 scored 0 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better in the afternoons |
| Cardiovascular | Negative | No ankle swelling |
| Musculoskeletal | Positive | Right ankle slightly sore after a long walk |
| Psychiatric | Negative | Mood steadier; cravings in the late afternoon, less strong; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake | One tablet by mouth twice a day, self-directed | Oral route | 2024-08-01 to 2026-08-04 | stopped | S |
| Losartan 50 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-08-04 to 2026-09-15 | completed | S |
| Losartan 100 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-09-15 | active | S |
| Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check | Up to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or driving | Oral route | 2026-08-04 to 2026-08-08 | completed | S |
| Thiamine 100 mg oral tablet once daily | One tablet by mouth daily | Oral route | 2026-08-04 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen | One to two tablets by mouth every six hours as needed; no more than four tablets a day | Oral route | 2026-08-04 | active | S |
| Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines | One tablet by mouth every morning | Oral route | 2026-08-18 | active | S |
| Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily | One tablet by mouth daily | Oral route | 2026-09-15 | active | S |
| Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicine | Apply 4 g to the ankle four times a day for up to seven days | Topical route | 2026-09-01 to 2026-09-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-15 | Body height | 173 | cm | S |
| 2026-09-15 | Body weight | 82.6 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 78 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-15 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-15 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-15 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-09-15 | Creatinine [Mass/volume] in Serum or Plasma | 1.96 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-09-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 44 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-09-15 | Albumin/Creatinine [Mass Ratio] in Urine | 128 | mg/g | Below 30 mg/g A1; 30 to 300 A2; above 300 A3 | High | S |
| 2026-09-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 10-40 U/L | Normal | S |
| 2026-09-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 9-46 U/L | Normal | S |
| 2026-09-15 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 82 | U/L | 8-61 U/L | High | S |
| 2026-09-15 | Phosphatidylethanol [Mass/volume] in Blood | 36 | ng/mL | Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking | High | S |
| 2026-09-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Low | S |
| 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2026-09-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 138/86, pulse 78; weight 82.6 kg |
| Cardiovascular | Regular rhythm; no edema |
| Musculoskeletal | Right ankle: slight swelling, mild tenderness over the anterior talofibular ligament; walks normally |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation | resolved | confirmed | R94.4 | S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease. |
| Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney disease | active | confirmed | N18.32 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys. |
| Hypertensive chronic kidney disease, untreated until intake | active | confirmed | I12.9 | S — Synthetic modern diagnosis made at the consultation. |
| Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL | active | confirmed | F10.20 | S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking. |
| Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intake | active | confirmed | K70.0 | S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver. |
| Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place | resolved | confirmed | Z79.1 | S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis. |
| Cigarette smoking, about ten a day; not ready to stop while he stops drinking | active | confirmed | F17.210 | S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim. |
| Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeks | active | confirmed | S93.401A | S — Synthetic acute injury; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 138/86 mmHg; home average 136/86 |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Six weeks on losartan 50 mg: potassium 4.8 mmol/L, creatinine 1.96 mg/dL; recheck four weeks after today's increase |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Completed today | eGFR 44; urine albumin 128 mg/g, down by about half |
| Laboratory | Electrolytes and bicarbonate | With each kidney test | Completed today | Sodium 140; bicarbonate 23 mmol/L |
| Laboratory | 25-hydroxyvitamin D | At baseline | Completed today | 24 ng/mL, insufficient; the test deferred from intake; vitamin D3 started |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | No oral NSAIDs; topical diclofenac for the sprain finished; acetaminophen within limits |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Less salt; swimming most days |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | One evening two weeks ago; none since |
| Laboratory | PEth | At baseline and every four to six weeks in early recovery | Completed today | 36 ng/mL, from 410 |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Completed today | AST 34, ALT 29, GGT 82 U/L at four weeks of naltrexone |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No nausea; no opioid; he declined to ask for one for the sprain |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery | Completed today | Four sessions; a plan for pain and late afternoons |
| Survey | PHQ-9 and GAD-7 | At intake and at follow-up | Completed today | PHQ-9 5, from 9; item 9 scored 0 |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | About ten a day; will discuss at the preventive visit |
Goal progress:
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Preventive visit in two weeks. Ten-week review with potassium, creatinine and PEth. Counseling weekly. The clinic or 988 at any hour. Next scheduled visit 2026-09-29: periodic adult preventive visit. [S]